Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tematropium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 6/20 | 0.58 |
| ▸ | CHRM3 known ✓ | P20309 | 4/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.58 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tematropium SCHEMBL29388056 | 0.92 | CHRM2 (0.67) | CHRM2CHRM1PABPC1BLMSMN1; SMN2 | |
| SCHEMBL6577643 | 0.76 | CHRM2 (0.60) | CHRM2CHRM1PABPC1BLMSMN1; SMN2 | |
| Methylhomatropine SCHEMBL17179980 | 0.75 | CHRM2 (1.00) | CHRM2CHRM1PABPC1BLMSMN1; SMN2 | |
| Methylhomatropine SCHEMBL30516140 | 0.75 | CHRM2 (1.00) | CHRM2CHRM1PABPC1BLMSMN1; SMN2 | |
| Methylhomatropine SCHEMBL16784195 | 0.75 | CHRM2 (1.00) | CHRM2CHRM1PABPC1BLMSMN1; SMN2 | |
| Methylatropine SCHEMBL34463463 | 0.74 | CHRM2 (1.00) | CHRM2CHRM1PABPC1BLMSMN1; SMN2 | |
| Methylatropine SCHEMBL824874 | 0.74 | CHRM2 (1.00) | CHRM2CHRM1PABPC1BLMSMN1; SMN2 | |
| Methylhomatropine SCHEMBL613580 | 0.74 | CHRM2 (0.97) | CHRM2CHRM1PABPC1BLMSMN1; SMN2 | |
| Methylhomatropine SCHEMBL20659943 | 0.74 | CHRM2 (0.97) | CHRM2CHRM1PABPC1BLMSMN1; SMN2 | |
| Methylhomatropine SCHEMBL77827 | 0.74 | CHRM2 (0.97) | CHRM2CHRM1PABPC1BLMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250339367-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12403090-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250255780-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-08-14 | — | — | US | disclosed |
| US-12310922-B2 | System and method for making personalized individual unit doses containing pharmaceutical actives | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-12290597-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| US-12171723-B2 | System and method for making personalized individual unit doses containing pharmaceutical actives | AQUESTIVE THERAPEUTICS, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| CN-118812643-A | Nibea albiflora swim bladder oligopeptide with immunity enhancing effect and application thereof | 浙江海洋大学 | 2024-10-22 | — | — | CN | disclosed |
| WO-2002007707-A2 | LINKAGE OF AGENTS USING MICROPARTICLES | PERICOR SCIENCE, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
| US-20020010208-A1 | Targeting a pharmaceutical agent to a noncentral nervous system tissue by administering a covalent conjugate of the drug and cis-docosahexanoic acid | LUITPOLD PHARMACEUTICALS, INC. | 2002-01-24 | — | — | US | disclosed |
| EP-1163011-A2 | FATTY ACID-ANTICANCER CONJUGATES AND USES THEREOF | Protarga Inc. (US) | 2001-12-19 | — | — | EP | disclosed |
| US-6267957-B1 | Attaching agents to tissue with transglutaminase and a transglutaminase substrate | PERICOR SCIENCE, INC. | 2001-07-31 | — | — | US | disclosed |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | LUITPOLD PHARMACEUTICALS, INC. | 2001-05-31 | — | — | US | disclosed |
| EP-1054998-A1 | TRANSGLUTAMINASE LINKAGE OF AGENTS TO TISSUE | Pericor Science, Inc. (US) | 2000-11-29 | — | — | EP | disclosed |
| WO-2000053231-A2 | FATTY ACID-ANTICANCER CONJUGATES AND USES THEREOF | PROTARGA, INC. (US) | 2000-09-14 | — | — | WO | disclosed |
| WO-1999036570-A2 | TRANSGLUTAMINASE LINKAGE OF AGENTS TO TISSUE | PERICOR SCIENCE INC (US) | 1999-07-22 | — | — | WO | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010208-A1 | Targeting a pharmaceutical agent to a noncentral nervous system tissue by administering a covalent conjugate of the drug and cis-docosahexanoic acid | FABP7, FADS2, ALOX5 | CHRM1 2229/4885CHRM3 621/4885CHRM2 1377/4885 |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | FABP7, FFAR2, FFAR4 | CHRM1 3136/4885CHRM3 1522/4885CHRM2 2104/4885 |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | CHRM1 312/4885CHRM3 560/4885CHRM2 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.